Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (111)	1/30/1999 9:50:00 PM
From: Mad2	Read Replies (1) \| Respond to of 5582

Dear Doc. The only part of my post that was opinion is "Very fishy in my opinion." which is of course my opinion. Everything else is factual. I do find the credibiltiy of this change in GUMM's direction questionable as 1) No public information is available for Zicam or Zinullose 2) Zicam web site discusses the history of Zicam and references some 1980's vintage publications on the common cold, indicates Zicam was developed in 1995 and goes on to reference a manuiscript in preparation by Dr. Hensley and Dr. Davidison 3) No papers can be found having been published by Dr. Hensley or Davidison on any topic, nor have they ever been cited in the media or medical fields indicating to me they aren't researchers. 4) Gel Tech is listed to be a wholesaler of pharmacology materials by ABI 5) Concerning the Medical and Scientific Opinions cited on the Zicam site, none of the experts cited recomend ZICAM but rather are "in support of the science behind ZICAM and the reasonableness of ZICAM's mechanism of action" I have e-mail Murray Grossan and will post the response if I get one. Dr. Richard L. Lubman - Referenced twice, both on the same subject of medical malpractice in 1994 (New York Times) Dr. Murray Grossan Number of references pertaining to a nasal irrigation device he invented. Has a web site ent-consult.com Fariba Ghodsian Ph.D. Follows is from a 1997 PR News Release from Trega Biosciences Trega Biosciences, Inc. (Nasdaq: TRGA) (formerly Houghten Pharmaceuticals, Inc.) today announced that Fariba F. Ghodsian, Ph.D., has assumed the duties of strategic and financial advisor and acting chief financial officer. She replaces Terence E. McMorrow who has resigned to pursue other opportunities. In her role, Dr. Ghodsian will be involved in investor relations, strategic planning and financial operations. Most recently a vice president and biotechnology analyst at Lehman Brothers, Dr. Ghodsian has held similar positions at Hancock Institutional Equity Services and Wedbush Morgan Securities. Prior to Dr. Ghodsian's career as an equity analyst, she was director of business development for MedClone, a privately held biotechnology company, and a research scientist for Allergan Pharmaceuticals. She also worked as a consultant for Wertheim Schroder where she was responsible for financial analyses on certain pharmaceutical, biotechnology, chemical and medical device companies. "Fariba's background in finance, research and corporate development make her ideally suited to assist a developing company like Trega. Her comprehensive and strategic perspective on the industry will be invaluable as the company pursues its development goals and the expansion of its partnering network," stated Robert S. Whitehead, Trega's president and chief executive officer. "We believe her multifaceted talents will complement the skills of the management team and we look forward to working with her. I have to admit that ZICAM makes a great story. What I don't understand is why haven't they conducted peer review studies and published some information prior to commercialization? Also who are they? Why work with Gumm Tech, why not with a company who has better marketing strength to retail channels? The fact that it is a great story and is being handled the way it is is the reason it looks fishy to me.